Monday, November 9, 2026

Back to the front page

Roblox: Capture This Moment

Roblox’s Q3 FY26 DAUs fell year over year for the first time, while bookings declined 12% to $1.7 billion.

From X

@convequity

Convequity on X

I think the Oracle credit story could look very different in 2028 and 2029 from what the market is pricing today. $ORCL has priced $10 billion of stock and $10 billion of bonds to fund its AI buildout. Management expects free cash flow to turn positive in the second half of fiscal 2028. The interesting part is how Oracle gets there. AI customers need the capacity, and those customers also have relationships with the suppliers building the infrastructure. Customer prepayments and supplier financing can move some of the funding further upstream rather than leaving Oracle to finance everything itself. I'd also watch whether support can extend further up the supply chain. The final cost of a data center is not the same as the underlying cost of the components, so there may be room for suppliers or their suppliers to provide credit backing with less exposure than the headline project value. The actual contracts and who bears losses matter here. Oracle's five-year CDS has been trading close to 300 basis points. I'm curious about the other side of that trade: who is underwriting the protection, and what happens if Oracle reaches positive free cash flow and the fear around AI infrastructure financing eases? Selling protection is still a risky bet. A premium can look attractive right up until the underlying credit deteriorates, and spreads can widen before the trade works. But if Oracle delivers the capacity and its customers pay for it, I think the picture in 2028–29 could be very different from today's gloomy consensus.

Vicor Update, Part Four

Vicor’s Federal Circuit hearing put Foxconn’s disputed patent license under pressure, reinforcing its AI server royalty model and licensing…

Floor & Decor 3Q26: Business Update

Floor & Decor’s 3Q26 sales rose 3% while comparable sales fell 1.4%; it cut 2027 openings to 10-15 as high mortgage rates pressure…

ADCT · long

Adc Therapeutics SA (adct)

ADC Therapeutics centers on ZYNLONTA, an approved CD19-directed antibody-drug conjugate, after shares rose from roughly $4.

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.